Zhifei Biological Products

Historical price data

Zhifei Biological Products is a major force in China's vaccine industry, with a mission to develop and provide high-quality, accessible vaccines to prevent infectious diseases. Its key achievements include the successful commercialization of a recombinant human papillomavirus (HPV) vaccine, a recombinant COVID-19 vaccine, and a portfolio of other preventive vaccines. The company's strategic direction focuses on leveraging its R&D and manufacturing capabilities to expand its product pipeline and solidify its domestic leadership while exploring international opportunities.

Core platform based on recombinant protein expression systems (e.g., E. coli, CHO cells) for the development of subunit vaccines, combined with conjugate and traditional vaccine technologies.

Zhifei faces competition from other major Chinese vaccine makers (Sinovac, CanSinoBIO, CNBG) and multinationals like Merck and GSK in specific categories. Its differentiation lies in its dominant domestic sales network, cost-advantaged manufacturing, and strong execution in bringing recombinant vaccines to the Chinese market.